All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

FDA clears investigational new drug application for CD19-directed CAR-NK therapy NKX019

By Claire Baker

Share:

May 4, 2021


On April 28, 2021, the U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application to evaluate NKX019 for relapsed or refractory (R/R) B-cell malignancies.

This decision permits the start of a phase I clinical trial investigating NKX019 for the treatment of patients with R/R B-cell malignancies, such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.

NKX019 is an allogeneic, CD19-directed chimeric antigen receptor (CAR)-natural killer (NK) cell therapy developed from the peripheral blood of healthy donors. The product undergoes genetic editing to express membrane-bound IL-15, a cytokine central to the survival, proliferation, persistence, and activity of NK cells.

NKX019 offers an off-the-shelf approach to cancer immunotherapy, and the phase I clinical trial is due to commence in the second half of 2021.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?